- Home
- BTAI vs WATT Comparison
BTAI vs WATT Comparison
Compare BTAI & WATT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- WATT
- Stock Information
- Founded
- BTAI 2017
- WATT 2012
- Country
- BTAI United States
- WATT United States
- Employees
- BTAI N/A
- WATT N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- WATT Radio And Television Broadcasting And Communications Equipment
- Sector
- BTAI Health Care
- WATT Technology
- Exchange
- BTAI Nasdaq
- WATT Nasdaq
- Market Cap
- BTAI 8.3M
- WATT 9.3M
- IPO Year
- BTAI 2018
- WATT 2014
- Fundamental
- Price
- BTAI $5.48
- WATT $7.71
- Analyst Decision
- BTAI Strong Buy
- WATT
- Analyst Count
- BTAI 4
- WATT 0
- Target Price
- BTAI $40.00
- WATT N/A
- AVG Volume (30 Days)
- BTAI 22.4M
- WATT 73.3K
- Earning Date
- BTAI 08-12-2025
- WATT 07-29-2025
- Dividend Yield
- BTAI N/A
- WATT N/A
- EPS Growth
- BTAI N/A
- WATT N/A
- EPS
- BTAI N/A
- WATT N/A
- Revenue
- BTAI $868,000.00
- WATT $1,976,000.00
- Revenue This Year
- BTAI N/A
- WATT $1,028.91
- Revenue Next Year
- BTAI $328.13
- WATT N/A
- P/E Ratio
- BTAI N/A
- WATT N/A
- Revenue Growth
- BTAI N/A
- WATT 434.05
- 52 Week Low
- BTAI $1.17
- WATT $3.67
- 52 Week High
- BTAI $13.36
- WATT $81.00
- Technical
- Relative Strength Index (RSI)
- BTAI 67.45
- WATT 37.08
- Support Level
- BTAI $1.30
- WATT $6.99
- Resistance Level
- BTAI $8.08
- WATT $8.41
- Average True Range (ATR)
- BTAI 1.23
- WATT 1.24
- MACD
- BTAI 0.33
- WATT -0.60
- Stochastic Oscillator
- BTAI 61.65
- WATT 14.98
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs, and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. The WPN technology provides a comprehensive suite of capabilities designed to power the next generation of wireless energy networks, seamlessly delivering power and data across diverse, battery-free device ecosystems. It enhances operational visibility, control, and intelligent business automation. Its products include Transmitter IC & Module, Receivers IC, Transmitter System, and Evaluation Kits.